H.C. Wainwright reiterates Alto Neuroscience stock rating at buy
H.C. Wainwright reiterated a Buy rating on Alto Neuroscience (ANRO) with a $60 price target. The stock is up 119% over the past year, trading at $31.15. The company reported Q3 2026 results, maintaining its 2027 Phase 2b readout timeline and 2030 cash runway. ALTO-207 trial results and FDA feedback are expected in late 2026 or early 2027. H.C. Wainwright raised its success probability for ALTO-207 to 40% and assigned a 5% probability to ALTO-203.
How this was made
The 30-second read
Why it matters
The analyst's higher target and rating could attract new buying interest, especially from investors focused on clinical‑stage biotech.
Market read
The rating upgrade is a catalyst for short‑term price movement in ANRO, with broader implications for the depression‑therapy biotech niche.
What to watch
Potential dilution from future financing needs and competition from other depression treatments.
Background
Alto Neuroscience reported Q3 2026 results, completed a Phase 1 trial of ALTO-207, and outlined its Phase 2b readout timeline. The analyst raised the probability of success for its lead program.
Ticker impact
H.C. Wainwright reiterated a Buy rating on Alto Neuroscience and raised its price target to $60, reflecting updated success probabilities for its ALTO-207 program.
likely upward pressure as investors price in the higher target and improved success odds.
The rating change is a fresh analyst action with a concrete new price target, which can move the share price in the short term.
Market effects
May boost sentiment toward biotech firms developing depression therapies.
Limited to U.S. biotech investors.
Low, as the news is company‑specific.
Counterpoint
The upgrade may be premature given the early stage of the trials and cash runway uncertainties.
Key entities
- companyAlto Neuroscience
Biotech firm developing ALTO-207 for treatment‑resistant depression.
- analystH.C. Wainwright
Equity research firm that issued the rating and price target.
